Agoracom Blog Home

Archive for the ‘Novamind Inc.’ Category

« Older Entries
Newer Entries »

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:17 AM on Saturday, July 31st, 2021

A weekly summary of Novamind news and media, including the announcement of the opening of our fifth location in Draper, Utah.

OPINION July 27, 2021

The Art and Science of Psychedelic Trip-Sitting

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, discuss the art and science of psychedelic trip-sitting.

Visit us at psychedelictherapyfrontiers.com to learn more, subscribe and catch up on previous episodes you may have missed.

FEATURES July 28, 2021

Potential for Exponential Increase in Healing

Gaining insurance coverage for off-label ketamine treatment of depression could help exponentially more people in their healing journeys. Off-label medicine isn’t covered by insurance.

“Our health care system does acknowledge and allow us to use medicines off-label. Probably 20 percent or more of all prescriptions are given that way.” – Novamind Chief Medical Officer Dr. Reid Robison

View all media

Novamind Opens 5th Location Specialized in Integrative Psychiatry for Patients with Treatment-Resistant Conditions

We are pleased to announce the completed the construction of a new clinic focused on integrative psychiatric care and clinical research in Draper, Utah. With the opening of the New Clinic, Novamind is on track to open four new locations in Utah by September 2021, doubling the size of its network to eight clinics.

“We are on a mission to reduce suffering and optimize wellness and are committed to shaping the future of psychedelic medicine in a responsible and accessible way,” said Dr. Reid Robison, Novamind’s Chief Medical Officer.

July 29, 2021

View all press releases

Back to the future: Psychedelic drugs in psychiatry

In an article for Harvard Health, Peter Grinspoon, MD, covers how psychedelics work, evidence for using psychedelics medicinally and the pros and cons. It’s an interesting read given his personal history with psychedelics, which dates back to when he was 14 and reading “Psychedelic Drugs Reconsidered.” He remembers the book urging “an open-minded reappraisal about the therapeutic potential of this class of drugs.” Anyone involved in psychedelics knows that not all conversations on the topic are open-minded. It’s why part of the mission to provide safe, legal access to psychedelics also includes an educational component. The more we can destigmatize psychedelics, the faster we can continue to push the renaissance forward. 

Psychedelic trips could soon be part of therapy — here’s what those sessions will look like

Have you ever wondered what psychedelic therapy looks like? This article provides an insight into that process. “You don’t just get thrown into it,” (Jennifer) Mitchell says. “It’s not Burning Man or something. It’s very thoughtful.” And it’s something we take very seriously at our Cedar Psychiatry clinics. We recently posted a blog about psychedelics and safety considerations. Read it here.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:10 AM on Saturday, July 17th, 2021

A weekly summary of Novamind news and media, including the announcement of Novamind’s selection as a research site for Bionomics’ PTSD clinical trial.

OPINION July 7, 2021

Is the Mystical Experience Necessary for Psychedelic Healing?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.

FEATURES July 7, 2021

The Future of Ketamine

Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.

“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.

View all media

Novamind Selected as Research Site for Bionomics’ PTSD Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.

“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.

July 8, 2021

View all press releases

Psychedelic Drug Psilocybin “Magic Mushrooms” Spurs Growth of Neural Connections Lost in Depression

Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly. 

Can LSD Treat Food Allergies? We Don’t Know, But It’s Already Been Patented

While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.

Follow @novamind_inc on Instagram

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , ,
Posted in Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:19 AM on Saturday, July 10th, 2021

A weekly summary of Novamind news and media, including the announcement of Novamind’s selection as a research site for Bionomics’ PTSD clinical trial.

OPINION July 7, 2021

Is the Mystical Experience Necessary for Psychedelic Healing?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison, Dr. Steve Thayer, and Derick Moody, PA-C discuss whether or not the mystical experience caused by many psychedelic medicines is a necessary factor for the healing they promote.

FEATURES July 7, 2021

The Future of Ketamine

Microdose covers ketamine’s history as an off-label treatment for depression, the FDA approval of Spravatoᵀᴹ (esketamine) and what the future looks like for these drugs. CEO Yaron Conforti and CMO Dr. Reid Robison were both interviewed for the article.

“Cost and accessibility are universal challenges we face in our healthcare system, and these will also apply to psilocybin, MDMA, and nearly every drug that comes to market, at least during the initial years of patent exclusivity,” said Robison.

View all media

Novamind Selected as Research Site for Bionomics’ PTSD Clinical Trial

We are pleased to announce that our wholly owned subsidiary, Cedar Clinical Research has been selected as a research site for a study titled “A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder”.

“This clinical trial leverages CCR’s established track record studying novel treatments for PTSD and other difficult to treat mental health conditions.” said Dr. Reid Robison, Chief Medical Officer of Novamind.

July 8, 2021

View all press releases

Psychedelic Drug Psilocybin “Magic Mushrooms” Spurs Growth of Neural Connections Lost in Depression

Larger and stronger neural connections. According to new research out of Yale, it’s all about the increased density of dendritic spines. “Small protrusions found on nerve cells which aid in the transmission of information between neurons. Chronic stress and depression are known to reduce the number of these neuronal connections.” If psilocybin can create larger and stronger neural connections, the potential for treating depression and creating lasting change improves significantly. 

Can LSD Treat Food Allergies? We Don’t Know, But It’s Already Been Patented

While “there have been no research studies in humans showing that LSD can treat allergies of any kind” one patent application hopes that one day LSD will be able to treat food allergies. The article references a story about a claim (not research- or evidence-based) that LSD cured a lifelong cat allergy and goes into more detail about the patent process and what might stand in the way of this one getting approved. “It’s based on luck.” And it’s another entrant to the race to patent psychedelics.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:55 AM on Saturday, July 3rd, 2021

A weekly summary of Novamind news and media, including the announcement of a new podcast hosted by Dr. Steve Thayer and Dr. Reid Robison.

OPINION June 30, 2021

How to Integrate a Psychedelic Experience into Everyday Life

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss how to integrate a psychedelic experience into everyday life.

OPINION June 30, 2021

Psychedelics and the Inner Healing Intelligence

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer are joined by Derick Moody, PA-C, to discuss the role that the inner healing intelligence plays in psychedelic medicine.

OPINION June 30, 2021

Spirituality and the Psychedelic Renaissance

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Reid Robison and Dr. Steve Thayer discuss the historically messy relationship between spirituality and modern psychiatry and the role that psychedelics are playing in a spiritual renaissance.

View all media

Novamind Launches Psychedelic Therapy Frontiers Podcast

The Podcast is hosted by Novamind’s Dr. Stephen Thayer, Clinical Director, Education & Training and Dr. Reid Robison, Chief Medical Officer. Weekly Podcast episodes feature conversations between Dr. Thayer and Dr. Robison about issues that are of special interest to the psychedelic medicine and research community.

“Psychedelics are the next frontier of psychiatric medicine, and we’re helping professionals learn more about our specialized practice with actionable information. The need for specialized tools in mental healthcare has never been greater,” said Dr. Thayer.

June 30, 2021

View all press releases

I Was Paralyzed by Severe Depression. Then Came Ketamine.

Zoe Boyer writes about her lifelong struggle with depression: “Over the years I tried every available treatment. I stayed in psychiatric hospitals, underwent years of therapy and tried a pharmacy’s worth of antidepressants, but my condition never improved. One day, I stumbled across an article on the use of ketamine as a promising treatment for severe, unresponsive depression.” After four sessions, everything changed. “When my brother got his first pair of glasses, he marveled that he could see individual leaves on trees. Ketamine felt a lot like that. To be in awe of simple pleasures felt like reason enough to live, and I was overcome with a quiet revelation: this is what it means to be content.” Zoe’s story is similar to many who have had life changing experiences with Ketamine. We see it every day at our Cedar Psychiatry clinics. This video shares the stories of just a few of the thousands of patients we’ve treated.

Bay Area Lawmaker’s Proposal To Decriminalize Psychedelics In California Gains Momentum

How one state senator’s bill to decriminalize psilocybin, MDMA, LSD, DMT, mescaline and ibogaine is gaining steam in California. Former army rangers and marine corps veterans are quoted about how psychedelics offered them something they found nowhere else: hope and lasting change. “I will say this unequivocally psychedelics have, and will, save veteran lives.”

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , ,
Posted in Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:02 AM on Saturday, June 26th, 2021

A weekly summary of Novamind news and media, including the announcement of Paul Thielking as Chief Scientific Officer. 

FEATURES June 21, 2021

A Long Term Play for Psychedelic Drug Development

Green Market Report covers our strategic investment of $1 million in a Stealth Mode Drug Development Company. Psychedellux recaps the top business stories in the psychedelic medicine industry.

Last week we announced a strategic investment of $1 million in a stealth mode drug development company based in the United States.

FEATURES June 22, 2021

Critical Help for Frontline Workers

Report on Psychedelics covers our Frontline KAP program, which addresses a glaring need for innovative mental health solutions to provide treatment to healthcare workers suffering stress and trauma caused by Covid-19.

COVID-19 put a toll on the mental health of frontline healthcare workers. Novamind and the Wholeness Center will launch a ketamine-assisted psychotherapy protocol, in Utah and Colorado.

View all media

Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer

Dr. Thielking will oversee all aspects of the Company’s investigator-led studies, originating within Novamind’s best-in-class research sites, and leveraging its contract research organization (CRO) expertise to pursue additional clinical trial mandates from leading psychedelic drug developers.

 “Advancing clinical research for psychedelic medicine to address treatment-resistant mental illnesses and supporting patients by developing novel approaches to care for underserved conditions like cancer-related depression, is the next step in my life’s work,” said Dr. Thielking.

June 23, 2021

View all press releases

Can Psychedelics Help Make Dying Easier?

It’s a lawsuit that may be more of an “educational vehicle” for the Justice Department and the DEA than a legal battle. Under Washington state’s Right to Try law, Erinn Baldeschwiler should have the right to use psilocybin therapeutically, but the DEA has denied her request. Baldeschwiler may only have two years left and doesn’t want those years to be marred by depression. This case could set a precedent for the future “if the case passes, the next doctor and patient who want access to psilocybin for end-of-life distress shouldn’t need to take it to court again.” We understand the positive impact psychedelic medicine can have and will watch this case closely as we prepare to bring more psychedelic-assisted psychotherapies to the world. This week, Novamind announced Dr. Paul Thielking as Chef Scientific Officer. Dr. Thielking will lead the development of Novamind’s psychedelic therapy protocols for conditions including cancer-related depression and end-of-life anxiety, available as treatments for clients and educational programs for clinicians. 

Canadian healthcare workers are taking magic mushrooms for training purposes. Here’s why

Could changing the approach to the medical model transform the way we treat people? It’s a concept Natasha Fearnley believes in. “I’m beginning to guide them [people] through their journey. And I can’t imagine doing that without ever having any psychedelic experience.” TheraPsil agrees. “The non-profit believes that in order for healthcare professionals to deliver this “unique therapeutic modality” it’s essential that they undergo their own psilocybin journeys and guide their peers through the psilocybin therapy process.” 

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , ,
Posted in Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:06 AM on Saturday, June 19th, 2021

A weekly summary of Novamind news and media, including the announcement of a US$1,000,000 strategic investment in a Stealth Mode Drug Development Company. 

Novamind to Present at the H.C. Wainwright Psychedelics Conference on June 17, 2021

“Novamind has over five years of operational expertise with psychedelic medicine, a track record of innovative treatment protocol development, and strong clinical research partnerships with blue-chip pharmaceutical companies,” said CEO Yaron Conforti. “I’m excited to share our vision for the next chapter of mental health treatment at the Conference.”

June 15, 2021

Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company

The Strategic Investment leverages Novamind’s expertise in patient recruitment and patient management for the Investee’s development of novel treatments for neuropsychiatric disorders.

June 17, 2021

View all press releases

‘People are desperate to heal’: The push for psychedelic-assisted therapy in Canada

Global News paints a compelling picture about the need for psychedelic-assisted therapy in Canada. “I just had so many different experiences, where all my questions that I had written out, everything was answered for me.” says Laurie Brooks, who was diagnosed with colon cancer at age 54. “I’m able now to deal with the emotions as they come, and to sit with them and hold them.” 

The 10 Most Important Health Breakthroughs You Missed During the Pandemic

It’s been a year of progress as many health breakthroughs happened while the public’s attention was rightfully focused on a Covid vaccine. Time covers some significant steps forward, including a malaria vaccine that could help save some 400,000 lives a year and the promising results of MDMA and psilocybin studies. It’s important to note the therapy aspect of the psychedelic studies. Both MDMA and psilocybin were given to participants in conjunction with therapy. Yes, these drugs are powerful and help provide the right mindset for improving mental health, but it’s the therapy that really creates lasting change. And it’s why that’s such a big part of what we do at Novamind. 

Atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Congratulations to Atai Life on listing to the Nasdaq. As an early strategic investor, we look forward to seeing Atai continue to deliver on its mission of “pioneering the development of highly effective mental health treatments.” Christian Angermayer

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:54 AM on Saturday, June 12th, 2021

A weekly summary of Novamind news and media, including the announcement of a new psychedelic therapy protocol for frontline healthcare workers.

FEATURES  June 7, 2021

A Quarter of Growth

Green Market Report covers our fiscal Q3 earnings in their Psychedellux recap of the top business stories in the psychedelic medicine industry.

Novamind reported total revenue of $1.8 million, a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics.

View all media

Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers

“Together with the Wholeness Center, we’re joining forces to offer a new therapy that will positively impact the people who show up every day and continue to provide critical healthcare for the public during—and after—this difficult time,” said Dr. Robison.

Click here to learn more about the Frontline KAP protocol

June 10, 2021

View all press releases

The Brain-Changing Magic of New Experiences

From GQ’s series on mental health comes a piece about the psychological reasons how new experiences can change how we perceive time and make us more resilient. It’s an interesting read and the author even compares trees blooming in spring to psychedelics. “Even the most mundane new experiences left me feeling genuinely elated.” There’s a reason for it too. From Dr. Laurie Santos, “Novel stimuli tend to activate regions of our brain that are associated with rewards.” At our Cedar Psychiatry clinics, we practice a holistic approach to mental health. Taking into account psychological, biological, social, environmental, and cultural influences. Learn more here.

Atai Life Sciences Announces Launch of Initial Public Offering

We’ve always believed in Atai’s vision to transform the treatment of mental health disorders. It’s why we became early strategic investment partners. Congratulations to Atai Life Sciences on launching their initial public offering. 

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:23 AM on Saturday, June 5th, 2021

A weekly summary of Novamind news and media, including a report of our fiscal Q3 financial results and operating highlights.

FEATURES  June 4, 2021

Psychedelic Healing,Here and Now

At Novamind, we’re preparing for the future of psychedelic medicine, but we’re also treating people today and the results have been life changing.

“This is the first treatment that’s ever given me any relief from suicidal ideations. It’s like they’re gone.”

FEATURES  June 1, 2021

More Than Just a Treatment for Depression

Novamind CMO Reid Robison speaks to the Toronto Sun about why ketamine is a game changer for treating eating disorders.

“I was sitting with people before, during and after treatment and I was blown away by what I saw. It’s not just a treatment for depression.”

FEATURES June 2, 2021

Growing at Scale

Behavioral Healthcare Executive covers our fiscal Q3 earnings report, detailing growth and forecasted clinic visits.

“Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter. With its previously announced plans to open 4 new clinics, doubling the size of its network, between July and September, Novamind said in its earnings report that it expects to increase patient volume to more than 65,000 clinic visits in 2021, which would represent a 225% increase year-over-year.”

View all media

Novamind Reports Fiscal Q3 Financial Results and Operating Highlights

“Since listing on the CSE this January, Novamind has demonstrated its ability to rapidly scale access to innovative mental health treatment and psychedelic medicine,” said Yaron Conforti, CEO and Director, Novamind. “The contract with Merck to research a promising new drug, leveraged our expertise in patient recruitment and patient management. Novamind will continue to execute on its aggressive growth initiatives in 2021, further expanding organically and through acquisitions ahead of the FDA’s anticipated approvals of MDMA and psilocybin.” 

June 1, 2021

View all press releases

Researchers to Hone In On Most Therapeutic Doses of LSD

Identifying the correct dose for therapeutic settings is a crucial step in the path towards optimizing the healing power of psychedelics. In this article, Psychedelic Spotlight details new research studying the optimal LSD dosage for the treatment of mental health disorders. We look forward to more research and clinical trials in the future and will prepare for the time when LSD can be used as a treatment option in our clinics. 

The psychologists signing up for psychedelic therapy training: ‘Amazing things can happen’

The promise of psychedelic medicine is too great to ignore for Campbell Townsend, an Australian-based psychologist who is training in psychedelic-assisted psychotherapy. The Australian government has recently committed $15m to psychedelic clinical trials and support is growing in that country. There is significant momentum growing. Staying at the forefront of psychedelic research, Novamind is currently developing protocols for ketamine-assisted psychotherapy that will standardize and provide best-practice treatment methods for the widespread use of psychedelic medicine.

Follow @novamind_inc on Instagram

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:24 AM on Saturday, May 29th, 2021

A weekly summary of Novamind news and media

FEATURES May 28, 2021

Laying the groundwork for the psychedelic revolution

Novamind COO Pierre Bou-Mansour discusses rapid expansion, staying consistent and Novamind’s ultimate goal.

“We want to set a new standard of mental healthcare, and be the network that patients prefer—to become a trusted partner for innovative mental healthcare.”

View all media

How a psychedelic 12-step program is saving lives

Focused on creating a safe space “to incorporate psychedelic medicine into recovery,” Dimitri M. is a living embodiment of the wounded healer. A former heroin addict whose life was changed by Ibogaine and a 12-step program. Since he’s gone on to form Psychedelics in Recovery and is holding up to 17 meetings a week over zoom. Access to psychedelic medicine in the right situation can be life-changing. Dr. Reid Robison calls psychedelics “therapy accelerators.” Learn more about our innovative approach to psychedelic medicine here. 

MAPS wins appeal and authorization to study MDMA in healthy volunteer therapists

A study that had been on hold for almost two years has been approved. MAPS will hold a phase 1 clinical trial of MDMA-assisted therapy for healthcare workers. Working in conjunction with the FDA, MAPS was able to win the appeal and help “improve the regulatory landscape for all future patients of psychedelic-assisted medicines.” The study “will measure development of self-compassion, professional quality of life, and professional burnout among clinicians delivering the treatment to patients.” This study will address a critical area of need for healthcare workers. 

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:49 AM on Saturday, May 8th, 2021

A weekly summary of Novamind news and media

FEATURES May 7, 2021

Novamind Expands Footprint of Psychedelic Clinics

Our CEO Yaron Conforti and CMO Reid Robison discuss the news of our clinic expansion and how this further develops our model for scaling across the U.S.

FEATURES May 5, 2021

Pierre Bou-Mansour Discusses the Initial Phase of Novamind’s National Expansion Strategy

Our Chief Operating Officer speaks with the Wall Street Reporter about our clinic expansion, the key drivers of our growth, and the importance of set and setting in our clinics.

View all media

Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics

May 4, 2021

View all press releases

A Psychedelic Drug Passes Big Test for PTSD Treatment

In a soon-to-be-published study, MDMA and therapy are showing promising results in the treatment of PTSD, with over 67 percent of participants no longer qualifying for a diagnosis two months after treatment.

Why Psychedelics, Big in the 1960s, Are Drawing New Interest Now

Long misunderstood, psychedelics are back in the spotlight as more and more research is being done on the efficacy and positive mental health benefits they hold.

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

« Older Entries
Newer Entries »